Burden Roberta E, Gormley Julie A, Jaquin Thomas J, Small Donna M, Quinn Derek J, Hegarty Shauna M, Ward Claire, Walker Brian, Johnston James A, Olwill Shane A, Scott Christopher J
School of Pharmacy, Queen's University Belfast, Belfast, United Kingdom.
Clin Cancer Res. 2009 Oct 1;15(19):6042-51. doi: 10.1158/1078-0432.CCR-09-1262. Epub 2009 Sep 29.
Cathepsin S is a cysteine protease that promotes the invasion of tumor and endothelial cells during cancer progression. Here we investigated the potential to target cathepsin S using an antagonistic antibody, Fsn0503, to block these tumorigenic effects.
A panel of monoclonal antibodies was raised to human cathepsin S. The effects of a selected antibody were subsequently determined using invasion and proteolysis assays. Endothelial cell tube formation and aorta sprouting assays were done to examine antiangiogenic effects. In vivo effects were also evaluated using HCT116 xenograft studies.
A selected cathepsin S antibody, Fsn0503, significantly blocked invasion of a range of tumor cell lines, most significantly HCT116 colorectal carcinoma cells, through inhibition of extracellular cathepsin S-mediated proteolysis. We subsequently found enhanced expression of cathepsin S in colorectal adenocarcinoma biopsies when compared with normal colon tissue. Moreover, Fsn0503 blocked endothelial cell capillary tube formation and aortic microvascular sprouting. We further showed that administration of Fsn0503 resulted in inhibition of tumor growth and neovascularization of HCT116 xenograft tumors.
These results show that blocking the invasive and proangiogenic effects of cathepsin S with antibody inhibitors may have therapeutic utility upon further preclinical and clinical evaluation.
组织蛋白酶S是一种半胱氨酸蛋白酶,在癌症进展过程中促进肿瘤细胞和内皮细胞的侵袭。在此,我们研究了使用拮抗抗体Fsn0503靶向组织蛋白酶S以阻断这些致瘤作用的潜力。
制备了一组针对人组织蛋白酶S的单克隆抗体。随后使用侵袭和蛋白水解试验确定所选抗体的作用。进行内皮细胞管形成和主动脉芽生试验以检查抗血管生成作用。还使用HCT116异种移植研究评估体内作用。
所选的组织蛋白酶S抗体Fsn0503通过抑制细胞外组织蛋白酶S介导的蛋白水解,显著阻断了一系列肿瘤细胞系的侵袭,对HCT116结肠癌细胞的阻断作用最为显著。随后我们发现,与正常结肠组织相比,结肠腺癌活检组织中组织蛋白酶S的表达增强。此外,Fsn0503阻断了内皮细胞毛细管形成和主动脉微血管芽生。我们进一步表明,给予Fsn0503可抑制HCT116异种移植肿瘤的生长和新生血管形成。
这些结果表明,用抗体抑制剂阻断组织蛋白酶S的侵袭和促血管生成作用,在进一步的临床前和临床评估后可能具有治疗效用。